DOCSLIB.ORG

The Erbb/HER Family of Protein-Tyrosine Kinases and Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Erbb/HER Family of Protein-Tyrosine Kinases and Cancer Pharmacological Research 79 (2014) 34–74 Contents lists available at ScienceDirect Pharmacological Research jo urnal homepage: www.elsevier.com/locate/yphrs Invited Review The ErbB/HER family of protein-tyrosine kinases and cancer ∗ Robert Roskoski Jr. Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742, USA a r t i c l e i n f o a b s t r a c t Article history: The human epidermal growth factor receptor (EGFR) family consists of four members that belong to the Received 7 November 2013 ErbB lineage of proteins (ErbB1–4). These receptors consist of a glycosylated extracellular domain, a sin- Accepted 8 November 2013 gle hydrophobic transmembrane segment, and an intracellular portion with a juxtamembrane segment, a protein kinase domain, and a carboxyterminal tail. Seven ligands bind to EGFR including epidermal This paper is dedicated to the memory of growth factor and transforming growth factor ␣, none bind to ErbB2, two bind to ErbB3, and seven lig- Dr. John W. Haycock (1949–2012) who ands bind to ErbB4. The ErbB proteins function as homo and heterodimers. The heterodimer consisting of prompted the author to write a review on the treatment of malignant diseases with ErbB2, which lacks a ligand, and ErbB3, which is kinase impaired, is surprisingly the most robust signaling targeted protein kinase inhibitors. complex of the ErbB family. Growth factor binding to EGFR induces a large conformational change in the extracellular domain, which leads to the exposure of a dimerization arm in domain II of the extracellular Chemical compounds studied in this article: segment. Two ligand-EGFR complexes unite to form a back-to-back dimer in which the ligands are on Afatinib (PubChem CID: 10184653) opposite sides of the aggregate. Following ligand binding, EGFR intracellular kinase domains form an Docetaxel (PubChem CID: 148124) asymmetric homodimer that resembles the heterodimer formed by cyclin and cyclin-dependent kinase. Doxorubicin (PubChem CID: 31703) The carboxyterminal lobe of the activator kinase of the dimer interacts with the amino-terminal lobe 5-Fluorouracil (PubChem CID: 3385) of the receiver kinase thereby leading to its allosteric stimulation. Downstream ErbB signaling mod- Erlotinib (PubChem CID: 176870) ules include the phosphatidylinositol 3-kinase/Akt (PKB) pathway, the Ras/Raf/MEK/ERK1/2 pathway, Gefitinib (PubChem CID: 123631) and the phospholipase C (PLC␥) pathway. Several malignancies are associated with the mutation or Lapatinib (PubChem CID: 208908) increased expression of members of the ErbB family including lung, breast, stomach, colorectal, head Oxaliplatin (PubChem CID: 5310940) Pemetrexed (PubChem CID: 446556) and neck, and pancreatic carcinomas and glioblastoma (a brain tumor). Gefitinib, erlotinib, and afa- Regorafenib (PubChem CID: 11167602) tinib are orally effective protein-kinase targeted quinazoline derivatives that are used in the treatment of ERBB1-mutant lung cancer. Lapatinib is an orally effective quinazoline derivative used in the treatment of Keywords: ErbB2-overexpressing breast cancer. Trastuzumab, pertuzumab, and ado-trastuzumab emtansine, which Breast cancer are given intravenously, are monoclonal antibodies that target the extracellular domain and are used for Colorectal cancer the treatment of ErbB2-positive breast cancer; ado-trastuzumab emtansine is an antibody-drug con- Monoclonal antibody therapy Non-small cell lung cancer jugate that delivers a cytotoxic drug to cells overexpressing ErbB2. Cetuximab and panitumumab are Small molecule protein kinase inhibitor monoclonal antibodies that target ErbB1 and are used in the treatment of colorectal cancer. Cancers Targeted cancer therapy treated with these targeted drugs eventually become resistant to them. The role of combinations of tar- geted drugs or targeted drugs with cytotoxic therapies is being explored in an effort to prevent or delay drug resistance in the treatment of these malignancies. © 2013 Elsevier Ltd. All rights reserved. Contents 1. Introduction . 35 2. Overview of the ErbB/HER protein kinase family and their ligands. 35 2.1. ErbB protein kinases. 35 2.2. ErbB ligands . 36 Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; ado-trastuzumab emtansine, ado-trastuzumab-DM1; AL, activation loop; AR, amphiregulin; BTC, beta- cellulin; C-spine, catalytic spine; CAQ, 4-(3-chloroanilino) quinazoline; CDK, cyclin-dependent kinase; CNS, central nervous system; CRC, colorectal cancer; EC, extracellular; EGFR, epidermal growth factor receptor; EPG, epigen; EPR, epiregulin; FDA, United States Food and Drug Administration; FISH, fluorescent in situ hybridization; HB-EGF, heparin-binding epidermal growth factor-like growth factor; Nrg, neuregulin; JM, juxtamembrane; mAb, monoclonal antibody; LE, ligand efficiency; LipE, lipophilic effi- ciency; NSCLC, non-small cell lung cancer; PI3K, phosphatidylinositol 3-kinase; PK, protein kinase; PLC, phospholipase C; PTEN, phosphatase and tensin homolog; R-spine, regulatory spine; TGF␣, transforming growth factor ␣; TM, transmembrane; VEGFR, vascular endothelial growth factor receptor; MW, molecular weight. ∗ Tel.: +1 828 891 5637; fax: +1 828 890 8130. E-mail address: [email protected] 1043-6618/$ – see front matter © 2013 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.phrs.2013.11.002 R. Roskoski Jr. / Pharmacological Research 79 (2014) 34–74 35 3. ErbB/HER protein-tyrosine kinase structure and function . 38 3.1. The extracellular ligand-binding domains . 38 3.2. Catalytic residues in the amino and carboxyterminal lobes of the active and dormant ErbB1 protein kinase domains . 39 3.3. Structures of the hydrophobic spines in the active and dormant ErbB1 protein kinase domain . 42 3.4. Activation of the ErbB protein kinases . 42 3.4.1. Asymmetric dimer formation . 42 3.4.2. Role of the juxtamembrane segment and transmembrane helices in enzymatic activation . 43 3.4.3. A functional model of EGFR . 45 4. ErbB/HER signaling and receptor down regulation. 45 4.1. ErbB signaling . 45 4.2. ErbB down regulation . 48 4.3. Nuclear localization and function of the ErbB family . 48 5. ErbB/HER family gene amplification, overexpression, mutation, and cancer . 50 5.1. Lung cancer . 50 5.1.1. Classification and general treatment . 50 5.1.2. Mutant ERBB1 oncogenic activation . 50 5.1.3. Targeted inhibition of mutant EGFR by gefitinib, erlotinib, and afatinib . 52 5.1.4. Mutant ERBB2 oncogenic activation and pharmacological inhibition in lung cancer . 55 5.2. Breast cancer . 56 5.2.1. Classification and general treatment . 56 5.2.2. Targeted breast cancer treatments . 56 5.2.3. Activating ERBB2 mutations and breast cancer . 59 5.2.4. BRCA1 and BRCA2 genes and breast cancer. 60 5.3. Gastric cancer. 60 5.4. Colorectal cancer . ..
Load more

Recommended publications
  • LEPTOMYCIN A+B Inhibitors of Nuclear-Cytoplasmic Transport Highlighthighlight Tomorrow’S Reagents Manufactured Today™ International Version
    PRODUCT FLYER LEPTOMYCIN A+B Inhibitors of Nuclear-Cytoplasmic Transport highlighthighlight Tomorrow’s Reagents Manufactured Today™ International Version Available Nuclear Transport at Best Prices! In eukaryotic cells, the enclosure of ge- 65nm long aqueous channel. Transport oc- netic information by the nucleus allows the curs by a variety of different pathways, de- spatial and temporal separation of DNA rep- fined by individual receptors and accessory Leptomycin A+B lication and transcription in the nucleus from soluble factors. Soluble factors selectively cytoplasmic protein synthesis. This compart- target substrates/cargo for import and ex- mentalization permits a high level of regula- port as well as deliver them to their appropri- Leptomycin A [LMA] tion of these processes, but at the same time ate intracellular destination. Macromolecules ALX-380-101-C050 50 µg necessitates a system of selective macromo- (cargo) transported through these channels ALX-380-101-C100 100 µg lecular transport between the nucleus and include proteins and RNA, as individual enti- An antifungal antibiotic that acts as an inhibitor cytoplasm [1, 2]. ties or as part of larger complexes such as the of nuclear export by interacting with CRM1/ex- The term nuclear-cytoplasmic transport ribosomal subunits. While small molecules portin-1. Inhibits nucleo-cytoplasmic transloca- such as ions and proteins of up to 60kDa tion of molecules such as the HIV-1 Rev protein refers to the movement of a large variety of and Rev-dependent export of mRNA. macromolecules both into and out of the can diffuse through the NPC, small proteins nucleus. actively cross the NPC in a carrier-mediated SOURCE: Isolated from Streptomyces sp.
    [Show full text]
  • Tyrosine Kinase – Role and Significance in Cancer
    Int. J. Med. Sci. 2004 1(2): 101-115 101 International Journal of Medical Sciences ISSN 1449-1907 www.medsci.org 2004 1(2):101-115 ©2004 Ivyspring International Publisher. All rights reserved Review Tyrosine kinase – Role and significance in Cancer Received: 2004.3.30 Accepted: 2004.5.15 Manash K. Paul and Anup K. Mukhopadhyay Published:2004.6.01 Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Sector-67, S.A.S Nagar, Mohali, Punjab, India-160062 Abstract Tyrosine kinases are important mediators of the signaling cascade, determining key roles in diverse biological processes like growth, differentiation, metabolism and apoptosis in response to external and internal stimuli. Recent advances have implicated the role of tyrosine kinases in the pathophysiology of cancer. Though their activity is tightly regulated in normal cells, they may acquire transforming functions due to mutation(s), overexpression and autocrine paracrine stimulation, leading to malignancy. Constitutive oncogenic activation in cancer cells can be blocked by selective tyrosine kinase inhibitors and thus considered as a promising approach for innovative genome based therapeutics. The modes of oncogenic activation and the different approaches for tyrosine kinase inhibition, like small molecule inhibitors, monoclonal antibodies, heat shock proteins, immunoconjugates, antisense and peptide drugs are reviewed in light of the important molecules. As angiogenesis is a major event in cancer growth and proliferation, tyrosine kinase inhibitors as a target for anti-angiogenesis can be aptly applied as a new mode of cancer therapy. The review concludes with a discussion on the application of modern techniques and knowledge of the kinome as means to gear up the tyrosine kinase drug discovery process.
    [Show full text]
  • MEDICAL Injectables & ONCOLOGY TREND REPORT™
    MEDICAL INJECTABLEs & ONCOLOGY TREND REPORT™ 2010 firsT edition ICORE HEALTHCARE www.ICOREHealthcare.com/Trends.AsPx letter to OuR readers 1 Injectable Drugs: Giving You the Data You Need It is my pleasure to present you with the 2010 ICORE For this first edition, we surveyed 60 medical, pharmacy, and Healthcare Medical Injectables & Oncology Trend clinical directors representing 146 million lives to get an understanding ReportTM. It is the first of what will be an annual of what payors are doing today and planning to do in the future to publication. The purpose of our investment in this manage the quality and cost of care for medical benefit injectables. report is straightforward: Back in 2003 when ICORE We then evaluated health plan medical benefit injectable claims such Healthcare first began assisting payors in managing that benchmarks and trends could be determined. medical injectables, no reference or benchmark data ICORE Healthcare’s mission has not changed in the past seven existed. Frankly, this has continued to be the case years: We serve as the center of medical injectable drug management. until the release of this report, since few, if any, benefit To this end, we believe this report is one additional resource to assist managers are able to review and assess medical benefit our customers, colleagues, and partners. injectable claims. I want to give special thanks to the Assessing medical injectable use, costs, and trends payors who served on our advisory is more critical now than ever, since five of the top board of this publication and 16 drugs in 2009 (based upon sales dollars) were who provided invaluable input specialty drugs, whereas it is expected that 11 drugs of into the report’s overall objective, the top 16 will be injectable or specialty products by content, and design.
    [Show full text]
  • The Effects of Leptomycin B on Hpv-Infected Cells
    THE EFFECTS OF LEPTOMYCIN B ON HPV-INFECTED CELLS Carol Elizabeth Jolly A Thesis Submitted for the Degree of PhD at the University of St Andrews 2008 Full metadata for this item is available in St Andrews Research Repository at: http://research-repository.st-andrews.ac.uk/ Please use this identifier to cite or link to this item: http://hdl.handle.net/10023/900 This item is protected by original copyright This item is licensed under a Creative Commons Licence The Effects of Leptomycin B on HPV-Infected Cells By Carol Elizabeth Jolly A thesis submitted to the University of St Andrews in partial fulfilment of the requirement of the degree of Doctor of Philosophy Bute Medical School October 2008 Contents Declaration ii Copyright declaration iii Acknowledgements iv – v Abbreviations vi - viii Abstract ix Table of Contents x - xiii List of Figures xiv - xvi List of Tables xvi i Declaration I, Carol Elizabeth Jolly, hereby certify that this thesis, which is approximately 58,000 words in length, has been written by me, that it is the record of work carried out by me and that it has not been submitted in any previous application for a higher degree. I was admitted as a research student in September, 2004 and as a candidate for the degree of Doctor of Philosophy Medicine in October, 2005; the higher study for which this is a record was carried out in the University of St Andrews between 2004 and 2008. Date I hereby certify that the candidate has fulfilled the conditions of the Resolution and Regulations appropriate for the degree of Doctor of Philosophy Medicine in the University of St Andrews and that the candidate is qualified to submit this thesis in application for that degree.
    [Show full text]
  • Nimotuzumab, an Antitumor Antibody That Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding While Permitting the Active Receptor Conformation
    Published OnlineFirst July 7, 2009; DOI: 10.1158/0008-5472.CAN-08-4518 Experimental Therapeutics, Molecular Targets, and Chemical Biology Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation Ariel Talavera,1,2 Rosmarie Friemann,2,3 Silvia Go´mez-Puerta,1 Carlos Martinez-Fleites,4 Greta Garrido,1 Ailem Rabasa,1 Alejandro Lo´pez-Requena,1 Amaury Pupo,1 Rune F. Johansen,3 Oliberto Sa´nchez,5 Ute Krengel,2 and Ernesto Moreno1 1Center of Molecular Immunology, Havana, Cuba; 2Department of Chemistry, University of Oslo, Oslo, Norway; and 3Center for Molecular and Behavioral Neuroscience, Institute of Medical Microbiology, University of Oslo, Rikshospitalet HF, Oslo, Norway; 4Department of Chemistry, University of York, Heslington, York, United Kingdom; and 5Center for Genetic Engineering and Biotechnology, Havana, Cuba Abstract region of the EGFR (eEGFR), leaving the dimerization ‘‘arm’’ in Overexpression of the epidermal growth factor (EGF) receptor domain II ready for binding a second monomer (4, 5). It has been (EGFR) in cancer cells correlates with tumor malignancy and shown that the eEGFR adopts a ‘‘tethered’’ or inactive conformation poor prognosis for cancer patients. For this reason, the EGFR in the absence of EGF (6). In this characteristic conformation, has become one of the main targets of anticancer therapies. the dimerization arm is hidden by interactions with domain IV, Structural data obtained in the last few years have revealed whereas domains I and III remain separated. Thus, to adopt the the molecular mechanism for ligand-induced EGFR dimeriza- ‘‘extended’’ or active conformation observed in the crystal structure tion and subsequent signal transduction, and also how this of the complex with EGF (4), the receptor must undergo a major signal is blocked by either monoclonal antibodies or small conformational change that brings together domains I and III (6).
    [Show full text]
  • KPT-350 (And Other XPO1 Inhibitors)
    Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. KPT-350 (and other XPO1 inhibitors) Evidence Summary CNS penetrant XPO1 inhibitor with pleiotropic effects. May protect against neuroinflammation and proteotoxic stress, but similar drugs show a poor benefit to side effect profile in cancer. Neuroprotective Benefit: KPT-350 may reduce neuroinflammation and partially alleviate nucleocytoplasmic transport defects, but effects are pleiotropic and dependent on cellular and environmental conditions. Aging and related health concerns: XPO1 inhibition may promote autophagy, but has pleiotropic effects and is only marginally beneficial in cancer. Safety: KPT-350 has not been clinically tested. Tested XPO1 inhibitors are associated with myelosuppression, gastrointestinal events, anorexia, low blood sodium, and neurological events. Poor benefit to side effect ratio in cancer. 1 Availability: In clinical trials and Dose: Oral administration KPT-350 research use Dose not established for KPT-350 Chemical formula: Half-life: Unknown for KPT-350 BBB: KPT-350 is penetrant C18H17F6N5O2 6-7 hours for selinexor MW: 449.3 g/mol SINEs terminal half-life ~24 hours Clinical trials: None completed for Observational studies: Evidence for KPT-350. Phase 1 in ALS is ongoing.
    [Show full text]
  • Targeted and Novel Therapy in Advanced Gastric Cancer Julie H
    Selim et al. Exp Hematol Oncol (2019) 8:25 https://doi.org/10.1186/s40164-019-0149-6 Experimental Hematology & Oncology REVIEW Open Access Targeted and novel therapy in advanced gastric cancer Julie H. Selim1 , Shagufta Shaheen2 , Wei‑Chun Sheu3 and Chung‑Tsen Hsueh4* Abstract The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal growth factor receptor 2 (HER2), mesenchymal–epithelial transition, epidermal growth factor receptor, mammalian target of rapamycin, claudin‑18.2, programmed death‑1 and DNA. Addition of trastuzumab to platinum‑ based chemotherapy has become standard of care as front‑line therapy in advanced GC overexpressing HER2. In the second‑line setting, ramucirumab with paclitaxel signifcantly improves overall survival compared to paclitaxel alone. For patients with refractory disease, apatinib, nivolumab, ramucirumab and TAS‑102 have demonstrated single‑agent activity with improved overall survival compared to placebo alone. Pembrolizumab has demonstrated more than 50% response rate in microsatellite instability‑high tumors, 15% response rate in tumors expressing programmed death ligand 1, and non‑inferior outcome in frst‑line treatment compared to chemotherapy. This review summarizes the current state and progress of research on targeted therapy for advanced GC. Keywords: Gastric cancer, Targeted therapy, Human epidermal growth factor receptor 2, Programmed death‑1, Vascular endothelial growth factor receptor 2 Background GC mortality which is consistent with overall decrease in Gastric cancer (GC), including adenocarcinoma of the GC-related deaths [4]. gastroesophageal junction (GEJ) and stomach, is the ffth Tere have been several eforts to perform large-scale most common cancer and the third leading cause of can- molecular profling and classifcation of GC.
    [Show full text]
  • Ephb3 Suppresses Non-Small-Cell Lung Cancer Metastasis Via a PP2A/RACK1/Akt Signalling Complex
    ARTICLE Received 7 Nov 2011 | Accepted 11 Jan 2012 | Published 7 Feb 2012 DOI: 10.1038/ncomms1675 EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex Guo Li1, Xiao-Dan Ji1, Hong Gao1, Jiang-Sha Zhao1, Jun-Feng Xu1, Zhi-Jian Sun1, Yue-Zhen Deng1, Shuo Shi1, Yu-Xiong Feng1, Yin-Qiu Zhu1, Tao Wang2, Jing-Jing Li1 & Dong Xie1 Eph receptors are implicated in regulating the malignant progression of cancer. Here we find that despite overexpression of EphB3 in human non-small-cell lung cancer, as reported previously, the expression of its cognate ligands, either ephrin-B1 or ephrin-B2, is significantly downregulated, leading to reduced tyrosine phosphorylation of EphB3. Forced activation of EphB3 kinase in EphB3-overexpressing non-small-cell lung cancer cells inhibits cell migratory capability in vitro as well as metastatic seeding in vivo. Furthermore, we identify a novel EphB3-binding protein, the receptor for activated C-kinase 1, which mediates the assembly of a ternary signal complex comprising protein phosphatase 2A, Akt and itself in response to EphB3 activation, leading to reduced Akt phosphorylation and subsequent inhibition of cell migration. Our study reveals a novel tumour-suppressive signalling pathway associated with kinase-activated EphB3 in non-small-cell lung cancer, and provides a potential therapeutic strategy by activating EphB3 signalling, thus inhibiting tumour metastasis. 1 Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Graduate School of Chinese Academy of Sciences, Shanghai 200031, China. 2 The Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University, Shanghai 200433, China.
    [Show full text]
  • Erbb3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor STEPHEN P
    MOLECULAR AND CELLULAR BIOLOGY, June 1994, p. 3550-3558 Vol. 14, No. 6 0270-7306/94/$04.00+0 Copyright C 1994, American Society for Microbiology ErbB3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor STEPHEN P. SOLTOFF,l* KERMIT L. CARRAWAY III,1 S. A. PRIGENT,2 W. G. GULLICK,2 AND LEWIS C. CANTLEY' Division of Signal Transduction, Department ofMedicine, Beth Israel Hospital, Boston, Massachusetts 02115,1 and Molecular Oncology Laboratory, ICRF Oncology Group, Hammersmith Hospital, London W12 OHS, United Kingdom2 Received 11 October 1993/Returned for modification 11 November 1993/Accepted 24 February 1994 Conflicting results concerning the ability of the epidermal growth factor (EGF) receptor to associate with and/or activate phosphatidylinositol (Ptdlns) 3-kinase have been published. Despite the ability of EGF to stimulate the production of Ptdlns 3-kinase products and to cause the appearance of PtdIns 3-kinase activity in antiphosphotyrosine immunoprecipitates in several cell lines, we did not detect EGF-stimulated Ptdlns 3-kinase activity in anti-EGF receptor immunoprecipitates. This result is consistent with the lack of a phosphorylated Tyr-X-X-Met motif, the p85 Src homology 2 (SH2) domain recognition sequence, in this receptor sequence. The EGF receptor homolog, ErbB2 protein, also lacks this motif. However, the ErbB3 protein has seven repeats of the Tyr-X-X-Met motif in the carboxy-terminal unique domain. Here we show that in A431 cells, which express both the EGF receptor and ErbB3, Ptdlns 3-kinase coprecipitates with the ErbB3 protein (pl80eR3) in response to EGF. p180B3 is also shown to be tyrosine phosphorylated in response to EGF.
    [Show full text]
  • The Antibody Zalutumumab Inhibits Epidermal Growth Factor Receptor Signaling by Limiting Intra- and Intermolecular Flexibility
    The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility Jeroen J. Lammerts van Bueren*, Wim K. Bleeker*, Annika Bra¨ nnstro¨ m†, Anne von Euler†, Magnus Jansson†, Matthias Peipp‡, Tanja Schneider-Merck‡, Thomas Valerius‡, Jan G. J. van de Winkel*§, and Paul W. H. I. Parren*¶ *Genmab, 3508 AD, Utrecht, The Netherlands; †Sidec, SE-164 40 Kista, Sweden; ‡Division of Nephrology and Hypertension, Christian-Albrecht-University, 24105 Kiel, Germany; and §Immunotherapy Laboratory, Department of Immunology, University Medical Centre Utrecht, 3584 EA, Utrecht, The Netherlands Edited by Michael Sela, Weizmann Institute of Science, Rehovot, Israel, and approved February 7, 2008 (received for review October 8, 2007) The epidermal growth factor receptor (EGFR) activates cellular intervene in EGFR signaling, as reflected by two classes of pathways controlling cell proliferation, differentiation, migration, anti-EGFR drugs that are currently used clinically: tyrosine and survival. It thus represents a valid therapeutic target for kinase inhibitors (TKIs) and monoclonal antibodies (mAbs). treating solid cancers. Here, we used an electron microscopy-based TKIs represent small-molecule inhibitors that block EGFR- technique (Protein Tomography) to study the structural rearrange- kinase activity by binding to the ATP-binding pocket, thereby ment accompanying activation and inhibition of native, individual, abrogating downstream EGFR signaling. The effects of TKI EGFR molecules. Reconstructed tomograms (3D density maps) seem to be primarily related to enzyme inhibition. showed a level of detail that allowed individual domains to be For mAbs, the mechanisms of action are more diverse and discerned. Monomeric, resting EGFR ectodomains demonstrated their relative contribution to antitumor activity is still being large flexibility, and a number of distinct conformations were investigated.
    [Show full text]
  • Human Ephb3 Antibody Antigen Affinity-Purified Polyclonal Sheep Igg Catalog Number: AF5667
    Human EphB3 Antibody Antigen Affinity-purified Polyclonal Sheep IgG Catalog Number: AF5667 DESCRIPTION Species Reactivity Human Specificity Detects human EphB3 in direct ELISAs and Western blots. In direct ELISAs, approximately 3% cross­reactivity with recombinant mouse EphB3 is observed, and less than 1% cross­reactivity with recombinant rat EphB1, recombinant human (rh) EphB2 and rhEphB4 is observed. Source Polyclonal Sheep IgG Purification Antigen Affinity­purified Immunogen Mouse myeloma cell line NS0­derived recombinant human EphB3 Leu38­Ala550 Accession # P54753 Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (­SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS. APPLICATIONS Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website. Recommended Sample Concentration Western Blot 1 µg/mL See Below DATA Western Blot Detection of Human EphB3 by Western Blot. Western blot shows lysates of SH­SY5Y human neuroblastoma cell line. PVDF Membrane was probed with 1 µg/mL of Sheep Anti­Human EphB3 Antigen Affinity­ purified Polyclonal Antibody (Catalog # AF5667) followed by HRP­ conjugated Anti­Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for EphB3 at approximately 110 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8. PREPARATION AND STORAGE Reconstitution Sterile PBS to a final concentration of 0.2 mg/mL. Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
    [Show full text]
  • PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
    PDGFRB FISH PRODUCT DATASHEET Proprietary Name: PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) Established Name: PDGFRB FISH for Gleevec in MDS/MPD INTENDED USE Humanitarian Device. Authorized by Federal law for use in the qualitative detection of PDGFRB gene rearrangement in patients with MDS/MPD. The effectiveness of this device for this use has not been demonstrated. Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner. PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) is an in vitro diagnostic test intended for the qualitative detection of PDGFRB gene rearrangement from fresh bone marrow samples of patients with MDS/MPD with a high index of suspicion based on karyotyping showing a 5q31~33 anomaly. The PDGFRB FISH assay is indicated as an aid in the selection of MDS/MPD patients for whom Gleevec® (imatinib mesylate) treatment is being considered. This assay is for professional use only and is to be performed at a single laboratory site. SUMMARY AND EXPLANATION OF THE TEST The PDGFRB FISH assay detects rearrangement of the PDGFRB locus at chromosome 5q31~33 in adult patients with myelodysplastic syndrome/myeloproliferative disease (MDS/MPD). The PDGFRB gene encodes a cell surface receptor tyrosine kinase that upon activation stimulates mesenchymal cell division. Rearrangement of PDGFRB has been demonstrated by classical cytogenetic analysis in an exceedingly small fraction of MDS/MPD patients (~1%), usually cases with a clinical phenotype of chronic myelomonocytic leukemia (CMML). In particular, these patients harbor a t(5:12)(q31;p12) translocation involving the PDGFRB and ETV6 genes.
    [Show full text]